As pharmaceutical companies modernize ERP environments, AI often dominates the conversation. Yet SAPinsider research and broader industry signals point to a more immediate test: whether integration, governance, cloud architecture, and audit-ready data flows can support regulated operations before generative AI or agentic automation can deliver measurable value.
The pharmaceutical industry’s push toward SAP S/4HANA Cloud is increasingly framed as part of a broader AI-driven modernization story. SAP’s investments in Business AI, Joule, SAP Business Technology Platform (SAP BTP), and data-driven automation have accelerated that narrative. But when life sciences organizations evaluate the realities of ERP transformation, a different pattern emerges. Integration, cloud architecture, process governance, and auditability continue to shape modernization priorities long before AI becomes a production operating model.
The distinction is practical because pharmaceutical companies rarely modernize ERP systems in isolation. Manufacturing execution systems, laboratory environments, quality platforms, serialization systems, supply chain applications, batch release processes, and financial controls all depend on information moving across highly regulated environments. In these organizations, AI capabilities are only as useful as the data, integrations, and governance frameworks supporting them.
Food & Drug Administration (FDA) guidance defines data integrity as the completeness, consistency, and accuracy of data, while 21 CFR Part 11 applies to certain electronic records and electronic signatures created, modified, maintained, archived, retrieved, or transmitted under FDA records requirements. That regulatory context changes the ERP modernization question. AI outputs may support analysis, exception identification, or decision support, but the underlying records, workflows, approvals, and system controls still need to withstand audit and inspection scrutiny.
Integration Is Still the Foundation
SAPinsider’s 2025 SAP S/4HANA Migration Benchmark Report shows why the AI narrative needs more precision. Respondents cited improved integrations with other SAP products, innovations, and line-of-business tools as one of the leading benefits from moving to SAP S/4HANA, rising from 33% in 2024 to 53% in 2025. Improved performance also reached 53%, while minimized downtime and improved end-user and business satisfaction each reached 40%. Reduced audit exposure came in at 30%, and improved process efficiencies at 28%.
By comparison, AI interest is material but more complicated. SAPinsider found that 54% of respondents were considering AI or generative AI in their SAP S/4HANA deployment, while 38% planned to use Joule and 34% planned to use SAP BTP AI Foundation. At the same time, 37% said they were not planning to use AI in their SAP landscape, showing that AI momentum is real but uneven.
The investment pattern points to the more immediate work. SAPinsider found that 61% of organizations in 2025 planned to leverage SAP BTP, up from 57% in 2024. SAP Integration Suite adoption rose from 33% in 2024 to 46% in 2025, reflecting a growing need for connectivity across hybrid IT environments.
For pharmaceutical manufacturers, that ordering is significant. Regulatory processes often span multiple systems, organizational functions, and external partners. A quality event may trigger manufacturing reviews, supply chain updates, inventory decisions, financial impacts, and compliance reporting requirements. Those activities require reliable data movement, traceability, and process ownership before AI can meaningfully contribute to decision-making.
Rather than replacing integration requirements, AI increases their importance. Generative AI tools may accelerate analysis, summarize information, or identify exceptions, but they still depend on trusted and accessible enterprise data. When a batch record, deviation, inventory movement, supplier event, and finance posting do not share a defensible data path, AI cannot repair the gap by labeling it insight.
SAP BTP Is Becoming a Strategic Layer
SAPinsider’s migration research also shows SAP BTP and SAP Integration Suite becoming more central to S/4HANA programs, suggesting that ERP modernization is increasingly shaped by the integration and extension layer around the core.
SAP positions SAP BTP as a platform for integrating, automating, extending, and building AI-supported business applications and processes across the enterprise. SAP Integration Suite now carries a similarly expanded role, with SAP positioning it as a way for AI agents to securely access data, connect systems, and take action across business processes through APIs, events, and integration services.
For pharmaceutical organizations, that role extends beyond connectivity. Modern integration platforms increasingly support governance, process visibility, security controls, and audit requirements that are essential in regulated environments. Integration is becoming part of the control model, not just the technical route between applications.
This shift also connects to clean-core ERP strategies. As organizations move to SAP S/4HANA Cloud, they are under pressure to reduce technical debt, limit core modifications, and move custom logic into cleaner extensions, integrations, and side-by-side services. For pharma companies with years of validated customizations and process-specific configuration, that is a major operating-model decision.
A clean core may improve upgradeability and innovation readiness, but it does not remove the need for specialized life sciences processes. Instead, it changes where those processes are designed, governed, integrated, validated, and maintained. That makes SAP BTP, Integration Suite, and related extension patterns central to whether pharma ERP programs can modernize without weakening control over regulated workflows.
Cloud Adoption Continues Along a Hybrid Path
Cloud migration remains a priority across the SAP ecosystem, but pharmaceutical companies continue to approach cloud adoption differently from less regulated industries. Many organizations need deployment models that balance modernization objectives with validation requirements, data residency considerations, and long-established quality processes.
SAP’s cloud ERP portfolio gives customers multiple paths, including SAP S/4HANA Cloud Public Edition, SAP S/4HANA Cloud Private Edition, and customer data center options for SAP Cloud ERP Private. For regulated life sciences organizations, those choices affect more than hosting. They shape validation strategy, data residency, operating control, audit trails, latency, and inspection readiness.
SAP’s own life sciences positioning reflects those requirements. SAP offers SAP S/4HANA Cloud for GxP, private edition, which it describes as helping life sciences companies reduce compliance burden through automated transaction-level compliance for changing FDA, EMA, and other GxP guidelines. SAP also positions its customer data center option for SAP ERP Cloud Private around local data residency, operational continuity, control of ERP data, and physical and logical control of critical systems.
The result is often a hybrid architecture rather than a simple public-cloud model. For life sciences organizations, the question is rarely whether cloud adoption will occur. The more common challenge is determining which workloads can move quickly, which require additional governance or validation, and which integrations need to be redesigned before they can support cloud ERP.
Get Our Free Weekly Newsletter
Legacy Complexity Still Sets the Pace
The pace of SAP modernization is accelerating, but legacy environments remain a defining factor for many enterprises. SAP says mainstream maintenance for SAP Business Suite 7 core applications runs until the end of 2027, followed by optional extended maintenance through the end of 2030 at an added premium. That deadline continues to shape ERP roadmaps, but the technical reality is not uniform across customers.
SAPinsider’s 2025 migration research found that 31% of respondents had already transitioned to SAP S/4HANA, while 26% were implementing and 21% were still evaluating the business case. That means a large share of SAP customers are still deciding how much legacy process design, customization, integration history, and data should move into the next ERP environment.
Large pharmaceutical organizations often maintain extensive integrations, highly customized business processes, and validated environments that cannot be replaced quickly. ERP systems may be connected to MES, LIMS, QMS, warehouse, serialization, planning, cold-chain, supplier, and regulatory systems. Each connection can carry process logic, compliance requirements, data dependencies, and validation history.
That reality continues to drive interest in phased migration strategies and selective data transition. A new implementation can reduce complexity, but it can also force hard decisions about historical data, process fit, and validation scope. A system conversion can preserve more of the existing model, but it may carry forward process debt. Selective data transition offers a middle path, but it also requires careful governance over which data, processes, and customizations move forward.
For regulated industries, minimizing business disruption can carry equal importance to adopting new capabilities. The most successful ERP path is not necessarily the cleanest technical option in isolation. It is the path that balances modernization, continuity, validation effort, audit evidence, integration risk, and long-term maintainability.
Sponsor Industry‑Grade Research
AI Value Depends on ERP Readiness
The rapid rise of generative AI has understandably shifted executive attention toward productivity gains and intelligent automation. McKinsey’s 2025 State of AI survey found that AI use has broadened across organizations, but most companies are still in experimentation or piloting phases, and enterprise-level financial impact remains limited. That pattern reinforces the gap between AI ambition and production value.
In pharma ERP, that gap often sits in the architecture. Integration maturity remains uneven across many enterprises. SAPinsider’s 2025 Enterprise Integration for SAP report found that only 18% of respondents had all systems fully integrated with real-time data flow. Another 40% had most systems integrated with limited manual processes, while 33% had only some systems integrated and manual processes still common; 9% continued to rely on heavily siloed systems with heavy manual workloads.
The same report found that respondents integrated an average of 35.7 applications with SAP solutions while using an average of 4.5 integration tools. Those figures point to the operational complexity behind many AI roadmaps. If the enterprise foundation depends on fragmented process ownership, manual reconciliation, legacy interfaces, and inconsistent governance, AI can amplify inconsistency rather than resolve it.
SAP Batch Release Hub for Life Sciences illustrates the practical direction of travel. SAP positions the solution around automating and simplifying batch release processes, reducing quality noncompliance risk, and integrating natively with SAP S/4HANA. The value proposition is not AI in isolation. It is controlled process execution, integrated quality data, and reduced manual work in a regulated process.
That is where pharma ERP modernization is likely to create value first. AI may help surface exceptions, summarize quality signals, assist planners, or accelerate financial and operational analysis. But those capabilities need trusted records, integrated workflows, governed data, and audit-ready controls underneath them.
What This Means for ERP Insiders
Pharma ERP teams need to solve integration before AI use cases expand. AI can help identify exceptions, summarize operational signals, and support decision-making, but only when the data path behind those signals is governed and defensible. CIOs and ERP leaders should treat SAP BTP, SAP Integration Suite, data governance, and validation planning as part of the AI foundation, not separate technical workstreams.
Cloud model selection needs compliance criteria from the start. Public cloud, private cloud, customer data center, and hybrid options carry different implications for validation, data residency, operating control, audit trails, and inspection readiness. Pharma leaders should map regulated processes, records, interfaces, and control requirements before choosing the cloud architecture that will carry SAP S/4HANA forward.
Audit evidence should be designed into the architecture. Pharma organizations cannot rely on AI outputs, dashboards, or automation claims if they cannot prove how records were created, changed, approved, and transmitted across systems. ERP, quality, compliance, and finance teams should make traceability, electronic records controls, validation documentation, and exception handling non-negotiable requirements in SAP S/4HANA Cloud programs.
